Peter McAllister

4.1k total citations
55 papers, 638 citations indexed

About

Peter McAllister is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Neurology. According to data from OpenAlex, Peter McAllister has authored 55 papers receiving a total of 638 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Psychiatry and Mental health, 17 papers in Pathology and Forensic Medicine and 12 papers in Neurology. Recurrent topics in Peter McAllister's work include Migraine and Headache Studies (35 papers), Trigeminal Neuralgia and Treatments (14 papers) and Botulinum Toxin and Related Neurological Disorders (10 papers). Peter McAllister is often cited by papers focused on Migraine and Headache Studies (35 papers), Trigeminal Neuralgia and Treatments (14 papers) and Botulinum Toxin and Related Neurological Disorders (10 papers). Peter McAllister collaborates with scholars based in United States, Denmark and Poland. Peter McAllister's co-authors include Roger Cady, Anders Ettrup, Jessica Ailani, Philippe Picaut, Fatma Gül, Thierry Deltombe, Christina Marciniak, Allison Brashear, Svetlana Khatkova and Jean‐Michel Graciès and has published in prestigious journals such as JAMA, Neurology and Current Biology.

In The Last Decade

Peter McAllister

48 papers receiving 622 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter McAllister United States 14 430 261 194 169 87 55 638
M. Gottschalk Germany 5 323 0.8× 492 1.9× 167 0.9× 38 0.2× 33 0.4× 15 720
Donna Taraborelli United States 7 230 0.5× 145 0.6× 73 0.4× 78 0.5× 7 0.1× 10 520
Pernille Iversen Denmark 13 168 0.4× 146 0.6× 86 0.4× 52 0.3× 8 0.1× 25 576
Ilaria Frattale Italy 14 521 1.2× 347 1.3× 87 0.4× 181 1.1× 3 0.0× 35 605
Fethi İdiman Türkiye 11 229 0.5× 203 0.8× 148 0.8× 86 0.5× 6 0.1× 25 470
Jason A. Berard Canada 12 87 0.2× 270 1.0× 85 0.4× 139 0.8× 6 0.1× 24 507
Nandini Mullatti United Kingdom 13 275 0.6× 28 0.1× 118 0.6× 59 0.3× 14 0.2× 21 492
Heather Downs United States 9 188 0.4× 29 0.1× 96 0.5× 158 0.9× 12 0.1× 14 479
Gianluca Floris Italy 16 75 0.2× 83 0.3× 434 2.2× 87 0.5× 8 0.1× 50 699
Tiziana Carandini Italy 18 130 0.3× 196 0.8× 124 0.6× 124 0.7× 3 0.0× 43 658

Countries citing papers authored by Peter McAllister

Since Specialization
Citations

This map shows the geographic impact of Peter McAllister's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter McAllister with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter McAllister more than expected).

Fields of papers citing papers by Peter McAllister

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter McAllister. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter McAllister. The network helps show where Peter McAllister may publish in the future.

Co-authorship network of co-authors of Peter McAllister

This figure shows the co-authorship network connecting the top 25 collaborators of Peter McAllister. A scholar is included among the top collaborators of Peter McAllister based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter McAllister. Peter McAllister is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ashina, Messoud, Peter McAllister, Charly Gaul, et al.. (2025). Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial. Cephalalgia. 45(11). 2235440354–2235440354.
2.
McAllister, Peter, Atul T. Patel, Aaron Ellenbogen, et al.. (2025). Long‐Term Safety and Efficacy of Repeat Treatments with DaxibotulinumtoxinA in Cervical Dystonia: Results from the ASPEN ‐Open‐Label Study. Movement Disorders Clinical Practice. 12(11). 1764–1773.
3.
Ailani, Jessica, Pranav Gandhi, Amber Trujillo Lalla, et al.. (2024). Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine. Headache The Journal of Head and Face Pain. 64(10). 1253–1263. 2 indexed citations
4.
McAllister, Peter, et al.. (2024). Patient self rated pain: headache versus migraine a retrospective chart review. Head & Face Medicine. 20(1). 63–63. 1 indexed citations
5.
Silberstein, Stephen D., et al.. (2023). A Novel Virtual-Based Comprehensive Clinical Approach to Headache Care. Journal of Clinical Medicine. 12(16). 5349–5349. 2 indexed citations
6.
7.
8.
McAllister, Peter, Paul Winner, Jessica Ailani, et al.. (2022). Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. The Journal of Headache and Pain. 23(1). 22–22. 8 indexed citations
9.
McAllister, Peter, et al.. (2022). Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. The Journal of Headache and Pain. 23(1). 112–112. 8 indexed citations
10.
McAllister, Peter, Lois Lamerato, Joshua M. Cohen, et al.. (2021). Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. The Journal of Headache and Pain. 22(1). 156–156. 24 indexed citations
11.
12.
Ford, Janet H., Virginia L. Stauffer, Peter McAllister, et al.. (2020). Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study. Quality of Life Research. 30(2). 455–464. 6 indexed citations
13.
McAllister, Peter, et al.. (2019). Efficacy of Fremanezumab in Migraine Patients Who Have Failed at Least One Prior Migraine Preventive Medication (P1.10-011). Neurology. 92(15_supplement). 2 indexed citations
14.
McAllister, Peter, Paul Yeung, Joshua M. Cohen, Sanjay Gandhi, & Ronghua Yang. (2019). Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients With Chronic Migraine: Results of a 1-Year Study (P2.10-015). Neurology. 92(15_supplement). 1 indexed citations
15.
McAllister, Peter, Lawrence C. Newman, Cristina Tassorelli, et al.. (2018). Efficacy of Erenumab For the Treatment of Patients with Episodic Migraine with Aura (P4.094). Neurology. 90(15_supplement). 3 indexed citations
16.
Schwedt, Todd J., Uwe Reuter, Stewart J. Tepper, et al.. (2018). Early onset of efficacy with erenumab in patients with episodic and chronic migraine. The Journal of Headache and Pain. 19(1). 92–92. 72 indexed citations
17.
Bergström, Anders, Nano Nagle, Yuan Chen, et al.. (2016). Deep Roots for Aboriginal Australian Y Chromosomes. Current Biology. 26(6). 809–813. 43 indexed citations
18.
McAllister, Peter, et al.. (2015). The blood and the bone: The collection of human remains and frontier violence in colonial-era Queensland. 17. 115. 3 indexed citations
19.
Nagle, Nano, Kaye N. Ballantyne, Mannis van Oven, et al.. (2015). Antiquity and diversity of aboriginal Australian Y‐chromosomes. American Journal of Physical Anthropology. 159(3). 367–381. 15 indexed citations
20.
Graciès, Jean‐Michel, Allison Brashear, Robert Jech, et al.. (2015). Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. The Lancet Neurology. 14(10). 992–1001. 147 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Gottschalk Breakdown of academic impact, for papers by Donna Taraborelli Breakdown of academic impact, for papers by Pernille Iversen Breakdown of academic impact, for papers by Ilaria Frattale Breakdown of academic impact, for papers by Fethi İdiman Breakdown of academic impact, for papers by Jason A. Berard Breakdown of academic impact, for papers by Nandini Mullatti Breakdown of academic impact, for papers by Heather Downs Breakdown of academic impact, for papers by Gianluca Floris Breakdown of academic impact, for papers by Tiziana Carandini
Rankless by CCL
2026